Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); HCV Study May Boost Guidelines
Tweet
Share
E-mailGet Alerts OSUR Hot Sheet
Price: $3.75 +0.27%
Rating Summary:
9 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
9 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on OraSure Technologies (NASDAQ: OSUR) price target of $14.00.
Canaccord analyst, Jeffrey Frelick, said, "The cost effectiveness of birth-cohort screening for HCV in the primary care setting was shown to be effective in a simulated model that was recently published in the Annals of Internal Medicine. We reiterate our BUY on OSUR shares on our view that new tests for HCV and HIV-OTC will provide multiple years of revenue growth."
For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.
Shares of OraSure Technologies closed at $9.89 yesterday.
Canaccord analyst, Jeffrey Frelick, said, "The cost effectiveness of birth-cohort screening for HCV in the primary care setting was shown to be effective in a simulated model that was recently published in the Annals of Internal Medicine. We reiterate our BUY on OSUR shares on our view that new tests for HCV and HIV-OTC will provide multiple years of revenue growth."
For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.
Shares of OraSure Technologies closed at $9.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
